

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

WEST☐ Generate Collection

L11: Entry 26 of 60

File: DWPI

Aug 29, 1990

DERWENT-ACC-NO: 1990-262338

DERWENT-WEEK: 199035

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Rectal compsn. contg. fatty acid-aminoacid condensate - to improve resorption of non peptide active ingredient, esp. chloramphenicol

INVENTOR: GABELTAHLM, V; HACKER, E ; KOSSOWICZ, J ; KRAUSE, D ; MILDE, K ; STRATLING, E J ; TILL, L

PRIORITY-DATA: 1989DD-0325946 (February 22, 1989)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 384283 A	August 29, 1990		000	
DD 293488 A	September 5, 1991		000	
JP 02264713 A	October 29, 1990		000	

INT-CL (IPC): A61K 9/02; A61K 31/16; A61K 47/18

ABSTRACTED-PUB-NO: EP 384283A

BASIC-ABSTRACT:

Pharmaceutical compsn. for rectal administration with enhanced activity, comprises, apart from the active ingredient (I), which is not a peptide, 0.1-20% of an amino acid/fatty acid condensate (A) as resorption- increasing component. (A) is derived from simple (or peptide-condensed) amino acids and 10-20, pref. 12-18C, fatty acids.

(A) are of natural or synthetic origin, or are obtd. by hydrolysis of natural materials. (I) is porpyphenazine or esp. chloramphenicol (Ia).

USE/ADVANTAGE - By improving rectal resorption, (A) allows the dose of (I) to be reduced and a quicker response to be achieved.

WEST

☐ Generate Collection

L11: Entry 23 of 60

File: DWPI

Apr 5, 1991

DERWENT-ACC-NO: 1991-144844

DERWENT-WEEK: 199120

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Topically applied steroid compsn. - contg. antiinflammatory ester having steroid with long chain fatty acid

PRIORITY-DATA: 1989JP-0217023 (August 22, 1989)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 03081286 A	April 5, 1991		000	

INT-CL (IPC): A61K 31/57; C07J 5/00

ABSTRACTED-PUB-NO: JP03081286A

BASIC-ABSTRACT:

An external prepn. of steroid which contains ester bonded cpds. of antiinflammatory activity having steroid with 12-22C long chained fatty acid, as active components. Steroid is selected from hydrocortisone, prednisolone, methylprednisolone, dexamethasone, and betamethasone; and long chained fatty acid is selected from myristic, palmitic, stearic, palmitoleic, oleic, linolic or linoleic acid and E.P.A.

USE/ADVANTAGE - By dermal admin. of this external prepn. to inflammatory part, ester bond is cleavaged according to grade of inflammation after dermal absorption, and the drug effect is manifested. However an excess portion permeates the skin without decomposition to transit into the blood stream and be detoxified in liver and excreted. Also the prepn. is administered at non-inflammatory part, it exists as inert ester, and excreted similar to excess portion. Accordingly, necessary dose of drug only acts to inflammatory part, and excess drug is excreted without causing side effect.

WEST☐ Generate Collection

L11: Entry 22 of 60

File: DWPI

May 16, 1991

DERWENT-ACC-NO: 1991-180100

DERWENT-WEEK: 199125

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Powder-free pre-mix prepn. for animal prophylaxis and feeding - contg. quinoxaline or quinolone deriv. and anti-dusting soln. of fatty acid ester on edible or inert carrier

PRIORITY-DATA: 1990ES-0000070 (January 11, 1990)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
ES 2019016 A	May 16, 1991		000	

INT-CL (IPC): A23K 1/16; A61K 9/08; A61K 47/08

ABSTRACTED-PUB-NO: ES 2019016A

BASIC-ABSTRACT:

The process consists of preparing a compsn. an active principle pref. derived from quinoxiline or quinolone in an anti-dusting liquid constituted by a 6-16C fatty acid soln. a polyol deriv. of glycerol or ethylene glycol, and a glycerol-polyethylene glycol ester of a 6-16C fatty acid such as the ricinoleate, which is added to an edible or inert carrier or mixt. of these (

WEST☐ Generate Collection

L11: Entry 18 of 60

File: DWPI

Jul 20, 1993

DERWENT-ACC-NO: 1993-261591

DERWENT-WEEK: 199333

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Liquids for use as antiinflammatory agents for treating e.g. rheumatoid arthritis - contain steroid, ethanol, medium chain fatty acid tri:glycerid e(s) and/or medium chain fatty acid propylene glycol(s)

PRIORITY-DATA: 1991JP-0360062 (December 27, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 05178748 A	July 20, 1993		012	A61K031/57

INT-CL (IPC): A61K 9/08; A61K 31/57; A61K 47/10; A61K 47/14

ABSTRACTED-PUB-NO: JP05178748A

BASIC-ABSTRACT:

Skin external liqs. contain steroids as effective component and ethanol, medium chain fatty acid triglycerides, and/or medium chain fatty acid propylene glycols as base components.

The skin external liqs. contain 0.01-3 wt./vol.% steroids as effective component and 20-90 wt./vol.% ethanol, 10-80 wt./vol.% medium chain fatty acid triglycerides, and/or medium chain fatty acid propylene glycols as base components.

More specifically, the steroids employed are prednisolon, dexamethasone, hydrocortisone, and other steroidal drugs. The medium chain fatty acids are pref. 4-10C fatty acids such as caproic acid, capric acid, and caprylic acid.

USE/ADVANTAGE - The liquids are useful as external antiinflammatory agents in the treatment of chronic rheumatoid arthritis, systemic lupus erythematosus, systemic scleroderma, periarteritis nodosa, and other disorders related to diffuse collagen disease. The liqs. with the claimed compsn. are responsible for the stabilisation of the steroids, thus the content being maintained unchanged for a prolonged period of time. Also, excellent transdermal absorption can be obtd. by addn. of the base components, resulting in high pharmacological efficacy of the drugs.

In an example, an amt. of ethanol was added to 1 wt./vol.% prednisolone sodium succinate and 39 wt./vol.% medium chain fatty acid triglyceride (Panasate 810). The mixt. was stirred into soln., which was then dild. with ethanol and the total amt. was made 100 wt./vol.% to give a liqui

WEST☐ Generate Collection

L11: Entry 6 of 60

File: DWPI

Jul 28, 1998

DERWENT-ACC-NO: 1998-462791

DERWENT-WEEK: 199842

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Absorption-promoting composition e.g. for use with external pharmaceutical
s - comprising an unsaturated fatty acid-containing phospholipid and a poly:ol

PRIORITY-DATA: 1997JP-0017838 (January 16, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 10194994 A	July 28, 1998		007	A61K047/10

INT-CL (IPC): A61K 7/00; A61K 47/10; A61K 47/24

ABSTRACTED-PUB-NO: JP10194994A

BASIC-ABSTRACT:

An absorption-promoting composition composed of an unsaturated fatty acid-containing phospholipid (I) and polyol (II), where the content of the polyol in the composition is higher than that of the phospholipid, is claimed.

USE - The present composition promotes dermal absorption of drugs, for example, antiinflammatory compounds such as indomethacin, methyl salicylate, mefenamic acid, and hydrocortisone.

ADVANTAGE - Use of both (I) and (II) gives a synergistic improvement in absorption.

WEST☐ Generate Collection

L11: Entry 3 of 60

File: DWPI

Sep 12, 2001

DERWENT-ACC-NO: 2000-376518

DERWENT-WEEK: 200155

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Serum free medium for cell culture, containing growth factors, lipids, and fatty acids, use particularly for chondrocyte and mesenchymal stem cells for cartilage and bone, avoids risk of serum pathogens

INVENTOR: CANCELEDDA, R; DOZIN, B

PRIORITY-DATA: 1998US-0107646 (November 9, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1131407 A1	September 12, 2001	E	000	C12N005/00
WO 200027996 A1	May 18, 2000	E	017	C12N005/00
AU 200013804 A	May 29, 2000		000	C12N005/00

INT-CL (IPC): C12N 5/00

ABSTRACTED-PUB-NO: WO 200027996A

BASIC-ABSTRACT:

NOVELTY - Serum free cell culture medium, comprising one or more growth factors, one or more sources of lipids and fatty acids, in a minimum essential basic medium.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a composition for the expansion of chondrocytes, comprising fibroblast growth factor (FGF)-2, a fatty acid source, ascorbic acid, dexamethasone and insulin;

(2) a composition for the expansion of chondrocytes, comprising a minimum essential medium, epidermal growth factor (EGF), platelet derived growth factor (PDGF)bb, FGF-2, ascorbic acid, linoleic acid, human serum albumin (HSA), beta -mercaptoethanol, dexamethasone, insulin, and human holo- and apo- transferrin;

(3) a composition for the maintenance of mesenchymal stem cells, comprising selenium, biotin, sodium pantotenate, leukemia inhibitory factor (LIF), stem cell factor (SCF), and insulin-like growth factor (IGF)-1; and

(4) a composition for the maintenance of mesenchymal stem cells, comprising a minimum essential medium, EGF, PDGFbb, FGF-2, LIF, SCF, IGF-1, ascorbic acid, cholesterol, HSA, beta -mercaptoethanol, dexamethasone, human holo- and apo-transferrin, selenium, biotin, and sodium pantotenate.

USE - The compositions are used for growth and proliferation of chondrocytes which are specific for cartilage, and mesenchymal stem cells which can be used for the replacement of bone, cartilage, and other tissues.

WEST

☐ Generate Collection

L11: Entry 35 of 60

File: DWPI

Jun 4, 1988

DERWENT-ACC-NO: 1988-194673

DERWENT-WEEK: 198828

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Compsns. for topical admin. - contain corticosteroid(s) dissolved in nicotinic and/or salicylic acid ester(s)

PRIORITY-DATA: 1986JP-0278121 (November 21, 1986)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 63132838 A	June 4, 1988		005	

INT-CL (IPC): A61K 31/57

ABSTRACTED-PUB-NO: JP63132838A

BASIC-ABSTRACT:

Compsn. for topical administration contains corticosteroids, and nicotic acid ester and/or salicylic acid ester.

The corticosteroid is pref. prednisolone, cortisone, triamcinolone, betametasone, hydrocortisone, dexamethasone, methylprednisolone, fluocinolone, triamcinolone-acetonide, dexamethasone valerate, etc. Nicotic acid ester is pref. of 1-6C alcohol, and salicylic acid ester is of 1-6C alcohol or ethyleneglycol ester. The amt. of ester is 10-60 wt.% of 1 wt.% of corticosteroid.

The compsn. can also contain absorption auxiliary agents (e.g. dimethylsulphoxide, dimethyl lactamide, dimethylformamide, propyleneglycol, etc. and ester cpds. of glycerol or polyglycerol and fatty acid or ether of alcohol (e.g. diglycerin monooleate, triglycerine monostearate, tetraglycerine monostearate, tetraglycerine monooleate, hexaglycerin mono oleate, etc.).

USE/ADVANTAGE - Corticosteroids dissolve easily in salicylic acid ester or/and nicotic acid ester and skin absorption of corticosteroid is improved.

WEST☐ Generate Collection

L11: Entry 40 of 60

File: DWPI

Mar 5, 1986

DERWENT-ACC-NO: 1986-063325

DERWENT-WEEK: 198610

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Topical compsn. for skin treatment - contg. antiinflammatory glucocorticoid in combination with essential fatty acid

INVENTOR: HORROBIN, D F

PRIORITY-DATA: 1984GB-0020771 (August 15, 1984)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 173478 A	March 5, 1986	E	017	
AU 8545864 A	February 20, 1986		000	
CA 1264670 A	January 23, 1990		000	
DE 3587741 G	March 17, 1994		000	A61K035/78
EP 173478 B1	February 2, 1994	E	008	A61K035/78
IE 62292 B	January 25, 1995		000	A61K009/06
JP 61056136 A	March 20, 1986		000	
ZA 8505916 A	February 5, 1986		000	

INT-CL (IPC): A61K 7/48; A61K 9/06; A61K 31/20; A61K 31/23; A61K 31/57; A61K 35/78; A61K 47/00; A61K 31/57; A61K 35/78; A61K 31/57; A61K 31/20; A61K 31/23

ABSTRACTED-PUB-NO: EP 173478A

BASIC-ABSTRACT:

A topical compsn. for skin treatment contains an antiinflammatory glucocorticoid (I) in combination with an essential fatty acid (EFA) of the n-6 or n-3 series or equivalent polyunsatd. fatty acid, as such or in the form of a physiologically acceptable deriv. which may be converted in the body. Suitable EFAs are gamma-linoleic acid (GLA), dihomo-gamma linoleic acid, the 22:4 and 22:5 n-6 EFAs, the 18:4, 20:4, 20:5, 22:5 and 22:6 n-3 EFAs and columbinic acid.

(I) is e.g. hydrocortisone, cortisone, betamethasone, dexamethasone, fluprednisolone, methylprednisolone, paramethasone, prednisone, prednisolone, triamcinolone, beclomethasone, clobetasol, cloprednol, cortivasol, deoxycortone, desonide, desoxymethasone diflucortolone, fluclorolone, fludrocortisone, flumethasone, flunisolide, fluocinolone, fluocinonide, fluocortolone, fluoromethalone, fluperolone, fluprednidene, flurandrenolone, formocortal, halcinonide, hydrocortamate, medrysone, methyl-prednisone, paramethasone, prednisolamate and prednylidene.

USE - The compsns. are used for treating inflammatory skin disorders e.g. contact dermatitis, atopic dermatitis, psoriasis and seborrhoeic dermatitis.

ABSTRACTED-PUB-NO:

EP 173478B EQUIVALENT-ABSTRACTS:

The use, for the manufacture of a medicament for combating the reduction of 1-series prostaglandin production and of free gamma-linolenic acid level in the skin in the course of anti-inflammatory glucocorticoid treatment of the skin, of the glucocorticoid in conjunction with one or more essential fatty acids, wherein

the or each said essential fatty acid is of the n-6 series, gamma-linolenic acid and its metabolites, and/or the m-3 series, delta-6,9,12,15-octadecatetraneoic acid and its metabolites, and wherein said medicament is a topical preparation containing by weight, 0.01 to 30% fatty acid and 0.01 to 10% glucocorticoid in a topical application base.

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
DWPI	15 and 11	1	<u>L14</u>
DWPI	112 and 11	0	<u>L13</u>
DWPI	15 and carrier	56	<u>L12</u>
DWPI	110 and composition	60	<u>L11</u>
DWPI	(16 or 11) and (15 or 14 or 13 or 13 or 17)	171	<u>L10</u>
DWPI	18 and (16 or 11) and (15 or 14 or 13 or 13 or 17)	5	<u>L9</u>
DWPI	conjugate or complex	146080	<u>L8</u>
DWPI	\$30quinoxaline or \$30quinoxalin	1856	<u>L7</u>
DWPI	fatty acid	55371	<u>L6</u>
DWPI	QUINOXALINE	1535	<u>L5</u>
DWPI	CROMOLYN OR CORTISONE OR HYDROCORTISONE OR BETAMETHASONE OR DEXAMETHASONE OR PREDNISONE	1981	<u>L4</u>
DWPI	CHLORAMPHENICOL OR CARBENICILLIN OR COLISTIN OR PENICILLIN adj1 G OR AMIKACIN OR GENTAMYCIN OR BACTRACIN OR VANCOMYCIN	2030	<u>L3</u>
DWPI	ANTIBACTERIAL OR BETA-LACTAM OR CEFOXITIN OR FORMAMIDOYLTHIENAMYCIN OR THIENAMYCIN OR NEOMYCIN OR KANAMYCIN OR TETRACYCLINE	28575	<u>L2</u>
DWPI	LINOLEIC OR LINOLENIC OR DECOSAHEXANOIC OR EICOSANOID OR EICOSANOIDS	3091	<u>L1</u>

WEST

End of Result Set



Generate Collection

L11: Entry 60 of 60

File: DWPI

DERWENT-ACC-NO: 1966-09887F

DERWENT-WEEK: 196800

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Solubilisation of hydrocortisone acetate

PRIORITY-DATA: 1961JP-0014676 (July 14, 1961)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 63024391 B			000	
CA 682476 A			000	
GB 950161 A			000	

ABSTRACTED-PUB-NO: JP63024391B

BASIC-ABSTRACT:

Preparation of a hydrocortisone acetate (I) composition in which the steroid is dissolved in a fatty acid diethanolamide.

Rapid acting administration of hydrocortisone acetate (I) in soln. for treating rheumatic, allergic and inflammatory conditions.

WEST☐ Generate Collection

L11: Entry 50 of 60

File: DWPI

Apr 24, 1982

DERWENT-ACC-NO: 1982-44813E

DERWENT-WEEK: 198222

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Rectally administrable cephalosporin or penicillin compsns. - contg. amino acid and ether nonionic surfactant to increase absorbability

PRIORITY-DATA: 1980JP-0142384 (October 14, 1980)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 57067513 A	April 24, 1982		008	

INT-CL (IPC): A61K 9/02; A61K 31/43

ABSTRACTED-PUB-NO: JP57067513A

BASIC-ABSTRACT:

The compsns. are prepd. by mixing a water soluble drug, amino acid and ether type nonionic surfactant with an oily base. The water soluble drug is at least one of penicillins of formula (I), cephalosporins of formula (II), and/or their water-soluble non-toxic salts. R1 is acyl residue of ampicillin, amoxycillin, carbenicillin, sulbenicillin, cyclacillin, cycloxacillin, cloxacillin, flucloxacillin, or piperacillin; X1, X2 and X3 are the corresp. substituents of cefazoline, ceftezole, cefalexin, cefalotin, cephapirin, cefacetrile, cefatrizine, cefoxitin and cefmetazole.

The ether-type surfactants increase absorbability of drugs upon rectal application but have strong tissue disturbing action. The combined use of surfactants with oily bases markedly reduces such disturbance and increases absorbability.

The oily bases include oils and fats such as peanut, coconut, olive, soybean, rapeseed, cotton seed, sesame, corn, rice bran and tsubaki oil, cacao butter, lard, wool grease, beef tallow, and their modified products by hydrogenation, acetylation, or fractionation; esters of 6-30C fatty acid with glycerol or 2-8C alcohol.